Opinion: Artificial intelligence and machine learning can be the backbones of a drug launch playbook
New tools can help drug makers better target patient populations and prescribers to lift the launch of a new drug.
The days of the blockbuster drug might not be over, but they are dwindling. As markets become more crowded, pharmaceutical companies are focusing their drug development strategies on specialized populations, such as individuals with rare diseases or those with genetic subsets of chronic conditions like cancer and diabetes and cardiovascular diseases.
Identifying a specific subgroup of patients from a niche population poses challenges for many companies.
The integration of artificial intelligence (AI) and machine learning (ML) in a drug development and launch playbook
